AR127254A1 - Ciertas octahidrofuro[3,4-b]pirazinas como moduladores del receptor de glp-1 - Google Patents

Ciertas octahidrofuro[3,4-b]pirazinas como moduladores del receptor de glp-1

Info

Publication number
AR127254A1
AR127254A1 ARP220102689A ARP220102689A AR127254A1 AR 127254 A1 AR127254 A1 AR 127254A1 AR P220102689 A ARP220102689 A AR P220102689A AR P220102689 A ARP220102689 A AR P220102689A AR 127254 A1 AR127254 A1 AR 127254A1
Authority
AR
Argentina
Prior art keywords
octahydrophide
pyrazines
glp
certain
receptor modulators
Prior art date
Application number
ARP220102689A
Other languages
English (en)
Inventor
Magnus Polla
Joakim Bergman
Johan Sundell
Jonas Brnalt
Johan Kajanus
Ekaterina Ratkova
Magnus Johansson
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR127254A1 publication Critical patent/AR127254A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Un compuesto de fórmula (1). Una composición farmacéutica que comprende un compuesto según una cualquiera de las reivindicaciones 1 a 8, o una sal farmacéuticamente aceptable del mismo, opcionalmente mezclado con un adyuvante, diluyente o portador farmacéuticamente aceptable.
ARP220102689A 2021-10-05 2022-10-05 Ciertas octahidrofuro[3,4-b]pirazinas como moduladores del receptor de glp-1 AR127254A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163262109P 2021-10-05 2021-10-05

Publications (1)

Publication Number Publication Date
AR127254A1 true AR127254A1 (es) 2024-01-03

Family

ID=84045110

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP220102689A AR127254A1 (es) 2021-10-05 2022-10-05 Ciertas octahidrofuro[3,4-b]pirazinas como moduladores del receptor de glp-1

Country Status (3)

Country Link
AR (1) AR127254A1 (es)
TW (1) TW202333721A (es)
WO (1) WO2023057414A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023164050A1 (en) * 2022-02-23 2023-08-31 Terns Pharmaceuticals, Inc. Compounds as glp-1r agonists

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102314286B1 (ko) 2016-12-16 2021-10-21 화이자 인코포레이티드 Glp-1 수용체 작용제 및 이의 용도
US10934279B2 (en) * 2018-06-13 2021-03-02 Pfizer Inc. GLP-1 receptor agonists and uses thereof
KR102538572B1 (ko) 2018-06-15 2023-06-01 화이자 인코포레이티드 Glp-1 수용체 효능제 및 그의 용도
US20220024901A1 (en) 2018-11-22 2022-01-27 Qilu Regor Therapeutics Inc. Glp-1r agonists and uses thereof
PE20220143A1 (es) 2019-04-12 2022-01-27 Qilu Regor Therapeutics Inc Agonistas de glp-1r y usos de los mismos
US20220387402A1 (en) 2019-05-20 2022-12-08 Pfizer Inc. Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases
TWI751585B (zh) 2019-06-28 2022-01-01 美商美國禮來大藥廠 類升糖素肽1受體促效劑
WO2021018023A1 (zh) 2019-08-01 2021-02-04 济南泰达领创医药技术有限公司 小分子glp-1受体调节剂
US11702404B2 (en) 2019-10-25 2023-07-18 Gilead Sciences, Inc. GLP-1R modulating compounds
KR102344561B1 (ko) 2019-11-15 2021-12-29 일동제약(주) Glp-1 수용체 작용제 및 이의 용도
CN114761395A (zh) 2019-12-02 2022-07-15 现代药品株式会社 Glp-1受体激动剂
BR112022010599A2 (pt) 2019-12-10 2022-08-16 Pfizer Formas sólidas de ácido 2-((4-((s)-2-(5-cloropiridin-2-il)-2-metilbenzo[d][1,3]dioxol-4-il)piperidin-1-il)metil)-1-(((s)-oxetan-2-il)metil)-1h-benzo[d]imidazol-6-carboxílico, sal de 1,3-dihidróxi-2-(hidroximetil)propan-2-amina
KR20220133271A (ko) 2020-01-29 2022-10-04 길리애드 사이언시즈, 인코포레이티드 Glp-1r 조절 화합물
WO2021160127A1 (en) 2020-02-13 2021-08-19 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
CN113493447A (zh) 2020-04-03 2021-10-12 山东轩竹医药科技有限公司 Glp-1受体激动剂
TW202144340A (zh) 2020-04-03 2021-12-01 大陸商江蘇恆瑞醫藥股份有限公司 稠合咪唑類衍生物、其製備方法及其在醫藥上的應用
US20230295154A1 (en) 2020-04-29 2023-09-21 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
NZ796075A (en) 2020-06-04 2023-04-28 Hangzhou Sciwind Biosciences Co Ltd Five-membered heteroaromatic imidazole compound and use thereof
WO2021249492A1 (zh) 2020-06-10 2021-12-16 南京明德新药研发有限公司 甲基取代的苯并二噁唑类化合物及其应用
CN113816948B (zh) 2020-06-19 2023-08-11 江苏恒瑞医药股份有限公司 稠合咪唑类衍生物、其制备方法及其在医药上的应用
TW202214610A (zh) 2020-06-19 2022-04-16 大陸商江蘇恆瑞醫藥股份有限公司 ６－側氧－３，６－二氫吡啶類衍生物、其製備方法及其在醫藥上的應用
CN113831337B (zh) 2020-06-24 2023-03-24 广州市恒诺康医药科技有限公司 Glp-1受体激动剂及其药物组合物和用途
JP2023537501A (ja) 2020-08-06 2023-09-01 ガシャーブラム・バイオ・インコーポレイテッド ヘテロ環ｇｌｐ－１アゴニスト
WO2022031994A1 (en) 2020-08-06 2022-02-10 Qilu Regor Therapeutics Inc. Glp-1r agonists and uses thereof
CN116507326A (zh) 2020-08-21 2023-07-28 拓臻制药公司 作为glp-1r激动剂的化合物
EP4204415A1 (en) 2020-08-28 2023-07-05 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
WO2022007979A1 (zh) 2020-09-01 2022-01-13 江苏恒瑞医药股份有限公司 稠合咪唑类衍生物、其制备方法及其在医药上的应用
WO2022068772A1 (zh) 2020-09-29 2022-04-07 深圳信立泰药业股份有限公司 一种苯并咪唑类衍生物及其制备方法和医药用途
CN116348464A (zh) 2020-10-12 2023-06-27 杭州中美华东制药有限公司 苯并咪唑酮类glp-1受体激动剂及其用途
EP4229050A1 (en) 2020-10-13 2023-08-23 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
JP2023546054A (ja) 2020-10-13 2023-11-01 ガシャーブラム・バイオ・インコーポレイテッド ヘテロ環ｇｌｐ－１アゴニスト
CN114478497B (zh) 2020-11-12 2023-10-20 杭州中美华东制药有限公司 芳基烷基酸类glp-1受体激动剂及其用途
US11851419B2 (en) 2020-11-20 2023-12-26 Gilead Sciences, Inc. GLP-1R modulating compounds
CA3200245A1 (en) 2020-11-27 2022-06-02 Junjun Wu Benzimidazole derivative and preparation method therefor and medical use thereof
CN114591296A (zh) 2020-12-02 2022-06-07 海思科医药集团股份有限公司 一种glp-1r激动剂及其在医药上的应用
CN114591308B (zh) 2020-12-03 2024-03-08 苏州闻泰医药科技有限公司 一类glp-1r受体激动剂化合物及其用途
CN114634510A (zh) 2020-12-16 2022-06-17 杭州中美华东制药有限公司 咪唑并吡啶衍生物及其用途
CN114763352A (zh) 2021-01-15 2022-07-19 海思科医药集团股份有限公司 一种glp-1受体激动剂及其在医药上的应用
CN114805336A (zh) 2021-01-20 2022-07-29 江苏恒瑞医药股份有限公司 稠合咪唑类化合物、其制备方法及其在医药上的应用
US20230089073A1 (en) 2021-01-28 2023-03-23 Carmot Therapeutics, Inc. Gpcr receptor agonists, pharmaceutical compositions comprising the same, and methods for their use
CN114907351A (zh) 2021-02-07 2022-08-16 杭州中美华东制药有限公司 三环类glp-1受体激动剂及其用途
WO2022184849A1 (en) 2021-03-04 2022-09-09 Les Laboratoires Servier Glp-1r agonists, uses and pharmaceutical compositions thereof
EP4304712A1 (en) 2021-03-11 2024-01-17 Gilead Sciences, Inc. Glp-1r modulating compounds
US20220298148A1 (en) 2021-03-11 2022-09-22 Gilead Sciences, Inc. Glp-1r modulating compounds
CN113480534B (zh) 2021-07-23 2022-05-13 广州必贝特医药股份有限公司 苯并咪唑或氮杂苯并咪唑-6-羧酸类化合物及其应用
CN114716423A (zh) 2022-05-20 2022-07-08 中国科学院上海药物研究所 5,6-二氢-1,2,4-三嗪类化合物及其作为glp-1受体激动剂的药学用途

Also Published As

Publication number Publication date
WO2023057414A1 (en) 2023-04-13
TW202333721A (zh) 2023-09-01

Similar Documents

Publication Publication Date Title
DOP2022000124A (es) Derivados de pirazolilo útiles como agentes anticancerígenos
CL2022001392A1 (es) Compuestos tricíclicos sustituidos
CL2019002204A1 (es) Compuestos inhibidores del vih.
BR112022012641A2 (pt) Compostos tricíclicos substituídos
CR20210504A (es) Compuestos tricíclicos condensados útiles como agentes anticancerígenos
AR093244A1 (es) Compuestos de benceno sustituidos utilizables en el tratamiento de trastornos mediados por ezh2
CU24487B1 (es) Compuestos de tetrahidroquinolinona sustituidos como moduladores de gamma ror
AR050914A1 (es) Agonista receptor de vasopresina peptidico
UY37774A (es) Compuestos 5-cianoindol sustituidos y usos de los mismos
AR127254A1 (es) Ciertas octahidrofuro[3,4-b]pirazinas como moduladores del receptor de glp-1
CL2020001817A1 (es) Moduladores del receptor c5a
CL2022000893A1 (es) Derivados de 2-azaspiro[3,4]octano como agonistas de m4
CL2013003646A1 (es) Compuestos derivados de trans-1-(3s.1r)-6-cloro-3-fenilindan-1-il)-1,2,2-trimetilpiperazina deuterados, con actividad en los receptores 5ht2, d1 y d2; proceso de preparacion; compuesto intermediario; composicion y combinacion farmaceutica; y su uso para el tratamiento de la psicosis, entre otros.
CO2022008313A2 (es) Compuestos químicos
ECSP22027784A (es) Derivados de 2–azaespiro[3.4]octano como agonistas de m4
AR126854A1 (es) Compuestos macrocíclicos para el tratamiento de cáncer
PE20181328A1 (es) Compuestos de dihidroquinolinsulfonamida de alquilo
DOP2019000299A (es) Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias
MX2022010673A (es) Nuevos compuestos macrociclicos, un proceso para su preparacion y composiciones farmaceuticas que los contienen.
UY38567A (es) Inhibidores de o-glucoproteína-2-acetamido-2-desoxi-3-d-glucopiranosidasa de éter bicíclico
CO2023000854A2 (es) Nuevo derivado de pirazol
EA202091481A1 (ru) Замещенные алкиниленовые соединения в качестве противораковых агентов
UY39625A (es) Derivados tricíclicos útiles como inhibidores de parp7
AR119317A1 (es) Un derivado de tetrahidroisoquinolina sustituido como modulador alostérico positivo de d1
CO2022004768A2 (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias

Legal Events

Date Code Title Description
FB Suspension of granting procedure